ImmunityBio partners with Accord Healthcare, Uniphar to expand ANKTIVA access in Europe

Bitget2026/11/04 13:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

ImmunityBio is collaborating with Accord Healthcare and Uniphar to expand European access to bladder cancer therapy ANKTIVA.
Accord provides commercial expertise and market access support; Uniphar handles supply chain and distribution services.
The first European patients received ANKTIVA with BCG in Germany and Austria for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
European Commission conditional marketing authorization in February 2026 covers all 27 EU member states plus Iceland, Norway and Liechtenstein.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104114389) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

ImmunityBio partners with Accord Healthcare, Uniphar to expand ANKTIVA access in Europe

You may also like

Crypto prices